Ovid Therapeutics price target lowered to $1.50 from $2 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Ovid Therapeutics (OVID) to $1.50 from $2 and keeps a Buy rating on the shares. Ovid currently trades at a negative enterprise value and remains slated to deliver multiple potential value inflection points over the next 12 months, the analyst tells investors in a research note.